{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:35:05Z","timestamp":1782484505062,"version":"3.54.5"},"reference-count":102,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["No. DS177"],"award-info":[{"award-number":["No. DS177"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Multiple myeloma (MM) is the second most common hematological malignancy. Despite the huge therapeutic progress thanks to the introduction of novel therapies, MM remains an incurable disease. Extensive research is currently ongoing to find new options. MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression at a post-transcriptional level. Aberrant expression of miRNAs in MM is common. Depending on their role in MM development, miRNAs have been reported as oncogenes and tumor suppressors. It was demonstrated that specific miRNA alterations using miRNA mimics or antagomirs can normalize the gene regulatory network and signaling pathways in the microenvironment and MM cells. These properties make miRNAs attractive targets in anti-myeloma therapy. However, only a few miRNA-based drugs have been entered into clinical trials. In this review, we discuss the role of the miRNAs in the pathogenesis of MM, their current status in preclinical\/clinical trials, and the mechanisms by which miRNAs can theoretically achieve therapeutic benefit in MM treatment.<\/jats:p>","DOI":"10.3390\/jpm12091428","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T01:50:51Z","timestamp":1661997051000},"page":"1428","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["MiRNA as a Potential Target for Multiple Myeloma Therapy\u2013Current Knowledge and Perspectives"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-394X","authenticated-orcid":false,"given":"Aneta","family":"Szudy-Szczyrek","sequence":"first","affiliation":[{"name":"Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ahern","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital Galway, H91 Galway, Ireland"},{"name":"National University of Ireland, H91 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital Galway, H91 Galway, Ireland"},{"name":"National University of Ireland, H91 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Szczyrek","sequence":"additional","affiliation":[{"name":"Chair and Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-950 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[{"name":"Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref_1","unstructured":"Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020, April 10). SEER Cancer Statistics Review, 1975\u20132017, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"ref_2","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: Challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"ref_3","unstructured":"(2022, May 17). GLOBOCAN 2020. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_4","unstructured":"(2022, May 20). Cancer Stat Facts: Myeloma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x","article-title":"Multiple myeloma: Almost all patients are cytogenetically abnormal","volume":"94","author":"Zandecki","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: Basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nebbioso, A., Tambaro, F.P., Dell\u2019Aversana, C., and Altucci, L. (2018). Cancer epigenetics: Moving forward. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007362"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/carcin\/bgs140","article-title":"microRNA involvement in human cancer","volume":"33","author":"Iorio","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ali Syeda, Z., Langden, S.S.S., Munkhzul, C., Lee, M., and Song, S.J. (2020). Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051723"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.pathol.4.110807.092222","article-title":"MicroRNAs in cancer","volume":"4","author":"Lee","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2174\/156800912802429274","article-title":"MicroRNAs in the pathobiology of multiple myeloma","volume":"12","author":"Lionetti","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/1389201015666140519104743","article-title":"MicroRNA and multiple myeloma: From laboratory findings to translational therapeutic approaches","volume":"15","author":"Rossi","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.leu.2403647","article-title":"Spanish Network on multiple myeloma (G03\/136), Spanish Network of Cancer Research Centers (C03\/10).Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment","volume":"19","author":"Almeida","year":"2005","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A., Rodr\u00edguez-Garc\u00eda, Y., Encinas, J., Maroto-Mart\u00edn, E., Castellano, E., Teixid\u00f3, J., and Mart\u00ednez-L\u00f3pez, J. (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers, 13.","DOI":"10.3390\/cancers13020217"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2014.03.002","article-title":"Extracellular vesicles: Emerging targets for cancer therapy","volume":"20","author":"Vader","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: Biology and emerging therapeutic opportunities","volume":"12","author":"Breakefield","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.1074\/jbc.M110.107821","article-title":"Secretory mechanisms and intercellular transfer of microRNAs in living cells","volume":"285","author":"Kosaka","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yexcr.2016.10.012","article-title":"Functional transferred DNA within extracellular vesicles","volume":"349","author":"Cai","year":"2016","journal-title":"Exp. Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2018.00018","article-title":"Exosome-based cell-cell communication in the tumor microenvironment","volume":"6","author":"Maia","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/bloodadvances.2019000403","article-title":"Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion","volume":"3","author":"Umezu","year":"2019","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1010428317694298","DOI":"10.1177\/1010428317694298","article-title":"EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma","volume":"39","author":"Ding","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13402-017-0338-4","article-title":"EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells","volume":"40","author":"Airoldi","year":"2017","journal-title":"Cell Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes","volume":"247","author":"Frassanito","year":"2019","journal-title":"J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41375-020-0947-1","article-title":"miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma","volume":"35","author":"Rossi","year":"2020","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","article-title":"miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.18632\/oncotarget.1747","article-title":"Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity","volume":"5","author":"Raimondi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: Implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/emboj.2012.192","article-title":"Regulation of human lung alveolar multipotent cells by a novel p38a MAPK\/miR-17-92 axis","volume":"31","author":"Guinot","year":"2012","journal-title":"EMBO J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2003-04-1048","article-title":"Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation","volume":"103","author":"Kretzschmar","year":"2004","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.05.017","article-title":"miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma","volume":"309","author":"Chen","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth","volume":"19","author":"Leone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.18632\/oncotarget.820","article-title":"In vitro and in vivo anti-tumor activity of miR-221\/222 inhibitors in multiple myeloma","volume":"4","author":"Cantafio","year":"2013","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/sj.onc.1210436","article-title":"mir-29 regulates Mcl-1 protein expression and apoptosis","volume":"26","author":"Mott","year":"2007","journal-title":"Oncogene"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/10428190902763517","article-title":"MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes","volume":"50","author":"Mraz","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.4161\/cc.26585","article-title":"miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells","volume":"12","author":"Amodio","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/10245332.2018.1502961","article-title":"miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1","volume":"24","author":"Wang","year":"2019","journal-title":"Hematology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/0008-5472.CAN-19-1077","article-title":"Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13258-019-00900-z","article-title":"miR-489 suppresses multiple myeloma cells growth through inhibition of LDHA-mediated aerobic glycolysis","volume":"42","author":"Wu","year":"2020","journal-title":"Genes Genom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/beta-catenin\/BCL9 pathway","volume":"74","author":"Zhao","year":"2014","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1538-7445.NONRNA15-A17","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-019-0184-x","article-title":"Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing","volume":"9","author":"Agnelli","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","first-page":"291","article-title":"Effects of miR-181a on the biological function of multiple myeloma","volume":"42","author":"Liu","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.febslet.2014.03.049","article-title":"Wild type p53 reactivation: From lab bench to clinic","volume":"588","author":"Selivanova","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/jcp.24669","article-title":"A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells","volume":"229","author":"Leotta","year":"2014","journal-title":"J. Cell Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1158\/0008-5472.CAN-08-1768","article-title":"Emerging role of miR-106b-25\/miR-17-92 clusters in the control of transforming growth factor beta signaling","volume":"68","author":"Petrocca","year":"2008","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10142-016-0519-7","article-title":"Integrative analysis of signaling pathways and diseases associated with the miR-106b\/25 cluster and their function study in berberine-induced multiple myeloma cells","volume":"17","author":"Gu","year":"2017","journal-title":"Funct. Integr. Genom."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/CBM-182182","article-title":"MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN","volume":"24","author":"Yuan","year":"2019","journal-title":"Cancer Biomark."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"BSR20182502","DOI":"10.1042\/BSR20182502","article-title":"Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma","volume":"39","author":"Che","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34\u2014A microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Front. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence","volume":"18","author":"Leone","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_62","first-page":"5433","article-title":"MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2","volume":"8","author":"Wu","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijbiomac.2018.10.207","article-title":"c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma","volume":"122","author":"Xiao","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/jcb.29309","article-title":"miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5","volume":"121","author":"Wu","year":"2020","journal-title":"J. Cell Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/leu.2015.124","article-title":"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo","volume":"29","author":"Morelli","year":"2015","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.omtn.2019.02.023","article-title":"miR-125b upregulates miR-34a and sequentially activates stress adaption and cell death mechanisms in multiple myeloma","volume":"16","author":"Misso","year":"2019","journal-title":"Mol. Nucleic Acids"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2012-01-401794","article-title":"Investigational agent MLN9708\/2238 targets tumor-suppressor miR33b in MM cells","volume":"120","author":"Tian","year":"2012","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2008-09-178228","article-title":"microRNA expression in the biology, prognosis, and therapy of Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Amodio, N., Cantafio, M.E.G., Botta, C., Agosti, V., Federico, C., Caracciolo, D., Ronchetti, D., Rossi, M., Driessen, C., and Neri, A. (2019). Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma. Cancers, 11.","DOI":"10.3390\/cancers11020236"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1038\/cddis.2012.175","article-title":"miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1","volume":"3","author":"Amodio","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Abdi, J., Rastgoo, N., Chen, Y., Chen, G.A., and Chang, H. (2019). Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6151-x"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-14-1437","article-title":"miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hon.2639","article-title":"Serum exosomal microRNAs as novel biomarkers for multiple myeloma","volume":"37","author":"Zhang","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"30876","DOI":"10.18632\/oncotarget.9021","article-title":"Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e16711","DOI":"10.1097\/MD.0000000000016711","article-title":"MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis","volume":"98","author":"Xu","year":"2019","journal-title":"Medicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.12394","article-title":"Improved risk stratification in myeloma using a micro RNA-based classifier","volume":"162","author":"Wu","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Mlak, R., Mielnik, M., Mazurek, M., Chocholska, S., Podgajna, M., Szczyrek, M., Homa-Mlak, I., Ma\u0142ecka-Massalska, T., and Hus, M. (2022). Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 11.","DOI":"10.3390\/cells11040752"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1038\/s41598-021-90424-y","article-title":"Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data","volume":"11","author":"Katiyar","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2831","DOI":"10.7717\/peerj.2831","article-title":"Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets","volume":"5","author":"Xiang","year":"2017","journal-title":"PeerJ"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijlh.13367","article-title":"MicroRNAs in urine as diagnostic biomarkers for multiple myeloma","volume":"43","author":"Li","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2017.05.010","article-title":"Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients","volume":"17","author":"Ren","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.3390\/ijms140714240","article-title":"Intercellular communication by exosome-derived microRNAs in cancer","volume":"14","author":"Hannafon","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: From biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S1321","DOI":"10.21037\/tcr.2017.09.29","article-title":"Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy","volume":"6","author":"Baldari","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/mp2002076","article-title":"MicroRNA delivery by cationic lipoplexes for lung cancer therapy","volume":"8","author":"Wu","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/10430340360535751","article-title":"Stability of mRNA\/cationic lipid lipoplexes in human and rat cerebrospinal fluid: Methods and evidence for nonviral mRNA gene delivery to the central nervous system","volume":"14","author":"Anderson","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jconrel.2013.09.027","article-title":"Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.biotechadv.2017.03.002","article-title":"Nanocarriers for microRNA delivery in cancer medicine","volume":"35","author":"Badiola","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"119489","DOI":"10.1016\/j.carbpol.2022.119489","article-title":"Chitosan nanocarriers for microRNA delivery and detection: A preliminary review with emphasis on cancer","volume":"290","author":"Sargazi","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1038\/srep17579","article-title":"Delivery of miR-34a by chitosan\/PLGA nanoplexes for the anticancer treatment of multiple myeloma","volume":"5","author":"Cosco","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acs.biomac.8b01553","article-title":"Nanogels enable efficient miRNA delivery and target gene downregulation in transfection-resistant multiple myeloma cells","volume":"20","author":"Zilkowski","year":"2019","journal-title":"Biomacromolecules"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.addr.2014.05.010","article-title":"Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells","volume":"81","author":"Tay","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e24527","DOI":"10.1002\/jcla.24527","article-title":"Generation of MiRNA sponge constructs targeting multiple MiRNAs","volume":"36","author":"Jie","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7150\/jca.16723","article-title":"Lentiviral CRISPR\/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells","volume":"8","author":"Huo","year":"2017","journal-title":"J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Coira, I.F., Rinc\u00f3n, R., and Cuendet, M. (2022). The Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAs. Cancers, 14.","DOI":"10.3390\/cancers14102348"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells","volume":"22","author":"Cantafio","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41375-018-0161-6","article-title":"Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche","volume":"32","author":"Tsukamoto","year":"2018","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/leu.2016.296","article-title":"The LIN28B\/let-7 axis is a novel therapeutic pathway in multiple myeloma","volume":"31","author":"Manier","year":"2017","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome + autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","article-title":"Targeting the miR-221\u2013222\/PUMA\/BAK\/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma: The Role of miR-221\/222 in Multiple Myeloma Dexamethasone Resistance","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/9\/1428\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:52Z","timestamp":1760142052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/9\/1428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":102,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["jpm12091428"],"URL":"https:\/\/doi.org\/10.3390\/jpm12091428","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}